Publication
Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.
Jing Li, Kaikai Chen, Shun Zhang, Yu Shen, Zhiwei Chen, Ding Xu, Hailong Liu, Haibo Shen
Urologic oncologySep 18, 2026PMID 42759308doi:10.1016/j.urolonc.2026.08.015 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
INTRODUCTION: For cisplatin-eligible muscle-invasive bladder cancer, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been a standard approach. With the advent of more effective systemic therapies, bladder-preserving strategies after favorable response have become an area…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.